Navigation Links
Hyperthermia With Chemotherapy Improves Sarcoma Healing

Co-operation between GSF and clinic improves outlook for sarcoma patients: Effectiveness of local, deep hyperthermia proved in phase III study .

Hyperthermia, combined with chemotherapy, improves the chances of healing and survival of patients with low-lying, soft tissue sarcomas.

At the Annual General Meeting of the American Society of Clinical Oncology (ASCO) in Chicago, which ended last week, the GSF scientist, Prof. Dr Rolf D. Issels, presented the results of the first, randomised, worldwide phase III study in which the effectiveness and superiority of the combined-therapy methods are proven, in comparison with results from chemotherapy alone.

The study of 341 high-risk patients with deep, local sarcomas shows a significant improvement in the response of the tumour and in the survival of those patients who were treated by means of a combination of chemotherapy and of local, deep hyperthermia, in addition to operative removal of the sarcoma. This combined therapy has been applied already to a large number of patients in advance of surgery.

The well respected study results from the Clinical Co-operation Group Hyperthermia, which has existed since 1999 between the GSF National Research Centre for Environment and Health in Munich-Neuherberg and the Grohadern Medical Centre of the University of Munich.

Their spectrum of research extends from clinical analysis of deep hyperthermia for cancer therapy up to biological research in the areas of immunobiology and cell biology.

The head of the Clinical Co-operation Group Hyperthermia, Prof. Dr Rolf Issels, has been working at GSF, since the mid-80s, on the use of local, deep hyperthermia as a cancer therapy.

From the beginning, tumours of soft tissues and bones, which start from the connective tissue and are called sarcomas, were taken as examples.

The scientists were especially interested together with related bi ological research - in the question whether certain sarcomas could be better treated with a combination of hyperthermia and other forms of therapy.

In the course of local, deep hyperthermia, tumours are warmed to 40-44 Celsius, with, the aid of electromagnetic waves. At temperatures of 42 C, cells begin to die, on account of the heat. The combination therapy developed at GSF and the Grohadern Medical Centre exploits the fact that tumour cells are more vulnerable at 40 C to the immune system and also to radiotherapy and chemotherapy.

In the past years, the results gained in the treatment of sarcomas have encouraged the research group to apply their knowledge to other forms of tumour.

At the present time, within the framework of a part body hyperthermia project plan, they are investigating whether the combination of chemotherapy and radiotherapy with hyperthermia leads to better treatment results in cases of colon and rectum cancers and of pancreatic carcinoma, as well.

Under the guidance of GSF, a Virtual Institute of Excellence has been founded between the Clinical Co-operation Group Hyperthermia at the Grohadern Medical Centre and the Medical Clinic Charite Berlin, in order to promote the project plan, which will initially be sponsored for three years by the Initiative and Networking Fund of the Helmholtz Association of German Research Centres.

The Scientific Technical Director of GSF, Prof. Dr Wess, regards this as a successful example of translational research. The concept of research in co-operation groups together with clinical partners and the creation of clinical research platforms is an essential prerequisite for the prompt application of knowledge from fundamental research to clinical practice and vice versa.

Contact the GSF Press Office: GSF - Forschungszentrum fr Umwelt und Gesundheit Abteilung Kommunikation Tel: 089/3187-2460 Fax 089/3187-3324 E-mail: oea@gsf. de


'"/>




Related medicine news :

1. Research Reveals Way to Speed Up Treatment of Deadly Malignant Hyperthermia
2. Acupuncture May Help Chemotherapy Side Effects
3. Chemotherapy Pill Has Fewer Side Effects Than IV
4. Survival rates in breast cancer patients improved with "Dose Dense Chemotherapy"
5. Therapy Boosts Chemotherapy Effects
6. Chemotherapy Effective for Bladder Cancer
7. New Method Of Delivering Chemotherapy
8. The Benefits Of Chemotherapy For Women With Ovarian Cancer
9. New Compound Could Strengthen The Effect Of Chemotherapy
10. Older Breast Cancer Patients Can Be Effectively Treated With Chemotherapy
11. Treating Testicular Cancer With A Single Dose Of Chemotherapy
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:5/4/2016)... ... May 04, 2016 , ... ... 2016, a powerful cellular therapy software application that helps blood and marrow transplant ... , Since Transtem’s initial launch, Mediware has continued to enhance core application features. ...
(Date:5/4/2016)... ... May 04, 2016 , ... International Conference on Obesity and ... 2016 at Las Vegas. It aims to bring together academicians, scientists, dietitians, surgeons, ... organizations across the globe; making the conference a perfect platform to share experience ...
(Date:5/3/2016)... ... May 04, 2016 , ... The National Association of Professional Women (NAPW) ... of the Year Circle. She is recognized with this prestigious distinction for leadership in ... than 850,000 members and over 200 operating Local Chapters. , “I’m pleased to welcome ...
(Date:5/3/2016)... ... , ... Sue Desmond-Hellmann, chief executive officer of the Bill & Melinda Gates ... possibility in her keynote address at Georgia State University’s spring commencement on ... rich experience as a scientist, physician and executive, Desmond-Hellmann leads the Gates Foundation’s efforts ...
(Date:5/3/2016)... Baltimore, Md. (PRWEB) , ... May 03, 2016 , ... ... devastating consequences of inappropriate or excessive levels of alcohol use. Alcohol and its ... fetal alcohol spectrum disorders to the susceptibility to strokes in those 65 years and ...
Breaking Medicine News(10 mins):
(Date:5/3/2016)... OSWEGO, Ore. , May 3, 2016 /PRNewswire/ ... endovascular medical technology, today announced Food and Drug ... cardiac resynchronization defibrillator that provides heart failure patients ... scans. Iperia devices also have remote monitoring with ... that adapts the heart rate in response to ...
(Date:5/3/2016)... , May 3, 2016   BIOTRONIK ... of extending care beyond the implant at the Heart ... 4-7 in San Francisco . ... delivering the highest quality of patient care and satisfaction ... cared for each and every tomorrow," said Marlou ...
(Date:5/3/2016)... 2016 Pharmaceutical giant Johnson & ... a woman who says its talc-based powder products caused ... Ristesund $5 million in compensatory damages and $50 ... http://photos.prnewswire.com/prnh/20160330/349511LOGO ) , This is the ... In February, the same court awarded $72 million to ...
Breaking Medicine Technology: